Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > 180 Degree Capital Corp. to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 and to Host a Conference Call on Tuesday, August 11, 2020

Abstract:
180 Degree Capital Corp. (NASDAQ: TURN) will announce its second quarter 2020 financial results on Monday, August 10, 2020, shortly after the close of the public markets. It will host a conference call on Tuesday, August 11, 2020, at 9am Eastern Time to discuss these results.

180 Degree Capital Corp. to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 and to Host a Conference Call on Tuesday, August 11, 2020

Montclair, NJ | Posted on August 7th, 2020

The dial-in information for the call is noted below:

U.S. Domestic Dial-In Number: (712) 770-4598

International Dial-In Numbers:
https://d1io3yog0oux5.cloudfront.net/180degreecapital/files/International-Dial-In-Numbers-4-2019.pdf

Passcode: 415049

Webcast: https://www.freeconferencecall.com/wall/180degreecapital

Presentation materials along with a replay of the meeting will be available on the Company's investor relations website at https://ir.180degreecapital.com/ir-calendar.

####

About 180 Degree Capital Corp.
180 Degree Capital Corp. (180) is a publicly traded registered closed-end fund focused on investing in and providing value-added assistance through constructive activism to what we believe are substantially undervalued small, publicly traded companies that have potential for significant turnarounds. Our goal is that the result of our constructive activism leads to a reversal in direction for the share price of these investee companies, i.e., a 180-degree turn. Detailed information about 180 and its holdings can be found on its website at www.180degreecapital.com.

Forward-Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's securities filings filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference and link to the website www.180degreecapital.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release. 180 is not responsible for the contents of third-party websites.

For more information, please click here

Contacts:
Press Contact:
Daniel B. Wolfe
180 Degree Capital Corp.
973-746-4500

Copyright © 180 Degree Capital Corp.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nano-microscope gives first direct observation of the magnetic properties of 2D materials: Discovery means new class of materials and technologies September 18th, 2020

Physicists make electrical nanolasers even smaller September 18th, 2020

Shape matters for light-activated nanocatalysts - Study: Pointed tips on aluminum 'octopods' increase catalytic reactivity September 18th, 2020

Aberrant electronic and structural alterations in pressure tuned perovskite NaOsO3 September 18th, 2020

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Invests Additional Capital in TheMaven, Inc. and Provides QTD Public Portfolio Update (+22.1% / +$0.32 Per Share) September 10th, 2020

Izon Science receives $10.5M investment from Bolton Equities: Christchurch-headquartered nanotech company secures investment to accelerate global growth; appoints top board chairman and directors July 28th, 2020

180 Degree Capital Corp. Reports Q1 2020 Results and Developments From Q2 2020 May 6th, 2020

180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020

Investments/IPO's/Splits

180 Degree Capital Corp. Invests Additional Capital in TheMaven, Inc. and Provides QTD Public Portfolio Update (+22.1% / +$0.32 Per Share) September 10th, 2020

Nanogate: Meeting of creditors on November 4, 2020 September 4th, 2020

Izon Science receives $10.5M investment from Bolton Equities: Christchurch-headquartered nanotech company secures investment to accelerate global growth; appoints top board chairman and directors July 28th, 2020

180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020

Announcements

Nano-microscope gives first direct observation of the magnetic properties of 2D materials: Discovery means new class of materials and technologies September 18th, 2020

Physicists make electrical nanolasers even smaller September 18th, 2020

Shape matters for light-activated nanocatalysts - Study: Pointed tips on aluminum 'octopods' increase catalytic reactivity September 18th, 2020

Aberrant electronic and structural alterations in pressure tuned perovskite NaOsO3 September 18th, 2020

Financial Reports

180 Degree Capital Corp. Reports Q1 2020 Results and Developments From Q2 2020 May 6th, 2020

180 Degree Capital Corp. Reports 15.9% Annual Increase and 0.3% Quarter Increase in Net Asset Value Per Share to $3.06 as of December 31, 2019 February 24th, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results January 24th, 2020

Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results November 25th, 2019

Events/Classes

Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment September 16th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences September 10th, 2020

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 September 2nd, 2020

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress August 28th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project